Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPATools Bozkurt, Murat Fani, Virgolini, Irene, Balogova, Sona, Beheshti, Mohsen, Rubello, Domenico, Decristoforo, Clemens, Ambrosini, Valentina, Kjaer, Andreas, Delgado-Bolton, Roberto, Kunikowska, Jolanta, Oyen, Wim J G, Chiti, Arturo, Giammarile, Francesco, Sundin, Anders und Fanti, Stefano (2017) Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA. European journal of nuclear medicine and molecular imaging, 44 (9). pp. 1588-1601. ISSN 1619-7089 ![[thumbnail of Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA]](https://eprints.vinzenzgruppe.at/style/images/fileicons/text.png)
Text (Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA)
EJNMMI 2017 Bozkurt.pdf Restricted to Nur registrierte Benutzer Download (379kB) KurzfassungPURPOSE & METHODS:
Neuroendocrine neoplasms are a heterogenous group of tumours, for which nuclear medicine plays an important role in the diagnostic work-up as well as in the targeted therapeutic options. This guideline is aimed to assist nuclear medicine physicians in recommending, performing, reporting and interpreting the results of somatostatin receptor (SSTR) PET/CT imaging using 68Ga-DOTA-conjugated peptides, as well as 18F-DOPA imaging for various neuroendocrine neoplasms.
RESULTS & CONCLUSION:
The previous procedural guideline by EANM regarding the use PET/CT tumour imaging with 68Ga-conjugated peptides has been revised and updated with the relevant and recent literature in the field with contribution of distinguished experts.
Actions (login required)
|
||||||||||||||
 |
|
|
Tools
Tools
